Multiple myeloma, also known as plasma cell myeloma, is a malignant cancer originating from plasma cells in the bone marrow, which normally produce antibodies to fight infections. In this disease, plasma cells become cancerous and proliferate uncontrollably, producing abnormal monoclonal proteins (M proteins) that accumulate in blood and urine, causing damage to bones, kidneys, and other organs. The abnormal cells lead to bone destruction resulting in lytic lesions, fractures, and hypercalcemia due to increased bone resorption, as well as kidney impairment, anemia, and immune suppression. Multiple myeloma is part of a spectrum of plasma cell disorders, including benign monoclonal gammopathy of undetermined significance (MGUS) and more aggressive forms such as plasma cell leukemia. The Durie-Salmon staging system assesses the disease based on tumor burden and clinical features: Stage I indicates low tumor burden with limited marrow involvement, hemoglobin above 10 g/dL, normal calcium under 12 mg/dL, minimal or no bone lesions, and low M protein levels; Stage II reflects intermediate tumor burden with hemoglobin between 8.5 and 10 g/dL, calcium between 12 and 14 mg/dL, some bone damage, and moderate M protein levels; Stage III signifies high tumor burden, hemoglobin less than 8.5 g/dL, calcium over 14 mg/dL, extensive bone lesions or fractures, and high M protein concentrations. The more recent International Staging System (ISS) refines prognosis using blood markers beta-2 microglobulin and albumin, categorizing patients into Stage I (low beta-2 microglobulin <3.5 mg/L and normal albumin ?3.5 g/dL), Stage II (intermediate levels), and Stage III (high beta-2 microglobulin ?5.5 mg/L), often associated with worse outcomes; it also incorporates cytogenetic abnormalities to further stratify risk and guide personalized treatment. These staging systems help determine prognosis and tailor treatment, as multiple myeloma can range from asymptomatic to rapidly progressive disease with diverse clinical manifestations.

Multiple myeloma risk factors include advancing age, as it is most commonly diagnosed in people over 65, with risk increasing as one gets older. Men have a higher likelihood of developing multiple myeloma compared to women. A family history of multiple myeloma or related plasma cell disorders raises an individuals risk, as does race African Americans have a significantly higher incidence of the disease than other ethnic groups. A personal history of monoclonal gammopathy of undetermined significance (MGUS), a benign precursor condition, also increases the risk, although not everyone with MGUS progresses to multiple myeloma. Environmental exposures such as benzene, pesticides, and certain workplace chemicals have been linked to a higher risk, as have previous cancer treatments like radiation therapy and some chemotherapies. Additionally, obesity has been identified as a contributing risk factor, with studies showing that overweight or obese individuals are more likely to develop multiple myeloma.

Multiple myeloma symptoms primarily result from the proliferation of abnormal plasma cells and the consequent damage to bones, kidneys, and other organs. One of the most prominent symptoms is bone pain, typically felt in the back, ribs, or hips, which occurs due to bone lesions, osteoporosis, and an increased likelihood of pathological fractures. Fatigue and general weakness are common and largely caused by anemia, a reduction in red blood cell production that also compromises the bodys ability to fight infections. Kidney dysfunction arises as abnormal proteins produced by myeloma cells accumulate and damage renal tissues, leading to symptoms such as swelling, nausea, and difficulty urinating. The immune system is weakened because these malignant plasma cells produce ineffective antibodies, resulting in increased susceptibility to infections including pneumonia, urinary tract infections, and skin infections. Elevated calcium levels in the blood, known as hypercalcemia, occur when calcium is released from damaged bones into the bloodstream, causing nausea, vomiting, constipation, mental confusion, and kidney impairment. Patients often experience unexplained weight loss and loss of appetite as the disease progresses. When multiple myeloma affects the spine or nervous system, it can lead to neurological symptoms like numbness, weakness, or loss of sensation in the limbs.

The diagnosis of plasma cell myeloma involves a combination of tests and procedures to confirm the presence of malignant plasma cells and assess the extent of disease. Blood tests are crucial and can reveal abnormalities such as elevated calcium levels, anemia, and the presence of monoclonal proteins (M proteins), with serum protein electrophoresis and immunofixation used specifically to detect these abnormal antibodies produced by cancerous plasma cells. Urine tests, particularly a 24-hour urine collection, help identify Bence-Jones proteins, which are light chains of these abnormal antibodies commonly found in myeloma patients. A bone marrow biopsy is performed by extracting a small sample of bone marrow, usually from the hip bone, to examine for cancerous plasma cells directly. Imaging studies, including X-rays, CT scans, MRI, and PET scans, are used to evaluate bone damage, detect tumors, and determine the extent of disease spread, which is critical for staging and treatment planning.

Treatment for multiple myeloma aims to control the disease, reduce symptoms, and improve quality of life through a combination of therapies. Chemotherapy is frequently used to kill myeloma cells and slow disease progression. Targeted therapies, such as proteasome inhibitors like bortezomib and immunomodulatory drugs such as lenalidomide, specifically disrupt molecules involved in myeloma cell growth. Stem cell transplantation is a key treatment option, with autologous transplants involving the collection and reinfusion of the patients own stem cells after high-dose chemotherapy to restore bone marrow function, while allogeneic transplants use stem cells from a healthy donor. Radiation therapy can be applied to shrink tumors and relieve bone pain caused by myeloma lesions. Bisphosphonates, like zoledronic acid, help strengthen bones and reduce the risk of fractures. Corticosteroids such as dexamethasone are used to decrease inflammation and manage symptoms.Immunotherapy, including monoclonal antibodies and advanced treatments like CAR T-cell therapy, is increasingly used to stimulate the immune system to target and destroy myeloma cells.

There are no known methods to completely prevent multiple myeloma, several risk reduction strategies can help lower the likelihood of developing the disease. Avoiding tobacco use and limiting excessive alcohol consumption are important, as these habits are linked to an increased risk of various cancers, including multiple myeloma. Maintaining a healthy weight through a balanced diet rich in fruits, vegetables, and whole grains supports overall health and may reduce risk as well. Individuals diagnosed with monoclonal gammopathy of undetermined significance (MGUS), a precursor condition, should have regular medical monitoring to detect any progression toward multiple myeloma early. Additionally, minimizing exposure to hazardous chemicals, particularly in work environments, can further decrease risk by reducing contact with potential carcinogens associated with the disease.

Current research on plasma cell myeloma focuses on advancing diagnostic methods to enable earlier detection and more precise monitoring of disease progression. Innovations in treatment are a major area of development, with promising new therapies including CAR T-cell therapy, bispecific antibodies, and next-generation proteasome inhibitors that aim to improve patient outcomes. Additionally, genetic research is being conducted to identify high-risk mutations, which could pave the way for personalized treatment approaches tailored to an individuals genetic profile, ultimately enhancing the effectiveness of therapy and patient care.

1. Is plasma cell myeloma curable? Multiple myeloma is currently not curable, but it is treatable. With advances in treatment, many people can manage the disease for extended periods and maintain a good quality of life. 2. Can multiple myeloma be detected early? Early detection is challenging, as symptoms often dont appear until the disease has progressed. Regular checkups and monitoring are important for individuals at high risk. 3. What is the survival rate for plasma cell myeloma? The survival rate depends on the stage at diagnosis and the response to treatment. With advancements in treatment, the 5-year survival rate for multiple myeloma has improved significantly. 4. Can multiple myeloma come back after treatment? Yes, multiple myeloma can relapse after treatment. However, newer therapies and ongoing monitoring can help manage relapsed disease effectively. 5. What is the role of stem cell transplantation? Stem cell transplantation can be a treatment option for eligible patients, particularly in those with relapsed or refractory myeloma. It can help prolong remission and improve outcomes.